Geriatric Exclusivity For Cancer Drugs Could Drive Needed Research – IoM Report
This article was originally published in The Pink Sheet Daily
Executive Summary
In a report that offers a number of recommendations related to cancer care, an IoM committee suggests a plan for awarding six months of added patent life to new cancer drugs that are studied in the elderly.